Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Profit After Tax: 2021-2025

Historic Profit After Tax for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$50.6 million.

  • Prime Medicine's Profit After Tax rose 3.69% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 9.99%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • Prime Medicine's Profit After Tax amounted to -$50.6 million in Q3 2025, which was up 3.82% from -$52.6 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Profit After Tax peaked at -$16.4 million during Q3 2021, and registered a low of -$65.6 million during Q4 2023.
  • Its 3-year average for Profit After Tax is -$49.9 million, with a median of -$50.7 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Profit After Tax was 37.56% (2022), while the steepest drop was 78.83% (2022).
  • Quarterly analysis of 5 years shows Prime Medicine's Profit After Tax stood at -$62.9 million in 2021, then surged by 37.56% to -$39.3 million in 2022, then tumbled by 67.10% to -$65.6 million in 2023, then spiked by 35.60% to -$42.3 million in 2024, then grew by 3.69% to -$50.6 million in 2025.
  • Its Profit After Tax stands at -$50.6 million for Q3 2025, versus -$52.6 million for Q2 2025 and -$51.9 million for Q1 2025.